Resistance to activated protein C is an anomaly described by Dahlbäck in 1993.
Bertina discovered in 1994 the presence of a mutation in the factor V (FV) gene.
This mutation leads to the replacement at position 506 of an arginine by a glutamine (Arg506Gln), which affects one of the sites of cleavage of FV by PCa. As a result, FV "resists" inactivation by PCa.
The mutated FV is referred to as FV Leiden. This factor V loses its function as a cofactor of the protein C system, that is to say of a system which inhibits coagulation; on the other hand, it retains its procoagulant properties. There are other cases of mutations related to the resistance of activated protein C.
- Designed for use on the majority of hemostasis analyzers.
- Minimum expiration date of 2 years after the date of manufacture.
- Specificity 100%
- Sensitivity 100%
- Clear discrimination between genotypes
- Specialized hemostasis
- Not affected by :
- Lupus anticoagulants
- Protein C / protein S
- Antithrombin
- Fibrinogen and abnormal PT
- FVIII / FX / TFPI / D-Dimers
- Unfractionated heparins (UFH) and low molecular weight heparins up to 1.0 IU / mL
- Vials suitable for hemostasis analyzers.
- Protocols are available on request.
- Excellent stability on board hemostasis analyzers.
- Excellent linearity over a large measurement area.
- 3 vials x 2mL R1: RVV-V (+ APC), lyophilized
- 3 vials x 2mL R2: RVV-V (- APC), lyophilized
- 3 vials x 4mL R3: prothrombin activator, lyophilized
- 3 vials x 2mL R4: plasma diluent, lyophilized
- 1 vial x 1mL FV-L negative control
- 1 vial x 1mL FV-L heterozygous control
